Working… Menu

AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00372944
Recruitment Status : Completed
First Posted : September 7, 2006
Last Update Posted : August 13, 2014
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to assess the efficacy and safety of AZD6244 (ARRY-142886)versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line therapy with gemcitabine. Following baseline assessments, a minimum of 64 patients in approximately 5-6 centers from the US will be treated with either AZD6244 or capecitabine. Treatment will be continued for as long as the patients receive clinical benefit. The status of all patients will be checked (whether they are still taking treatment or not) approximately 3 months after the last patient has entered the study.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: AZD6244 Drug: capecitabine Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
Study Start Date : August 2006
Actual Primary Completion Date : April 2008
Actual Study Completion Date : October 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: 1
Drug: capecitabine
oral tablet
Other Name: Xeloda®

Experimental: 2
Drug: AZD6244
oral capsule
Other Name: ARRY-142886

Primary Outcome Measures :
  1. Median time to death (TTD) [ Time Frame: Data cut off for this analysis was 5th April 2008. ]
    The TTD (days) was calculated as the interval from date of randomisation to date of patient death (from any cause). Patients who had not died at the time of the final analysis were censored at the last date the patient was known to be alive. Median TTD in days is presented here.

Secondary Outcome Measures :
  1. Progression event count [ Time Frame: The mandatory tumour assessment visit (MTAV) occurred on 27th February 2008 (+/-3days) ]
    The number of patients with a progression event occurring on or before MTAV where an event is defined as Objective and/or clinical disease progression as measured using RECIST criteria, or death from any cause

  2. To assess the safety and tolerability of AZD6244 in the treatment of advanced or metastatic pancreatic cancer by review of adverse events (AEs) and laboratory parameters. [ Time Frame: Review of AEs for duration of study, from First Subject in August 2006 to Last Subject Last visit October 2008 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed with pancreatic cancer
  • Have failed first line gemcitabine therapy

Exclusion Criteria:

  • Previous therapy with EGFR inhibitor, MEK inhibitor or capecitabine.
  • Any recent surgery, unhealed surgical incision or severe condition such as uncontrolled cardiac disease or chronic gastrointestinal diseases.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00372944

Layout table for location information
United States, California
Research Site
Alhambra, California, United States
Research Site
Bakersfield, California, United States
Research Site
Palm Springs, California, United States
Research Site
Santa Maria, California, United States
United States, Florida
Research Site
Orlando, Florida, United States
United States, Maryland
Research Site
Chevy Chase, Maryland, United States
United States, Michigan
Research Site
Ann Arbor, Michigan, United States
United States, New York
Research Site
New York, New York, United States
United States, Tennessee
Research Site
Nashville, Tennessee, United States
United States, Texas
Research Site
Temple, Texas, United States
United States, Washington
Research Site
Seattle, Washington, United States
Research Site
Heidelburg, Australia
Research Site
Plovdiv, Bulgaria
Research Site
Sofia, Bulgaria
Research Site
Varna, Bulgaria
Research Site
Budapest, Hungary
Research Site
Cluj-Napoca, Romania
Sponsors and Collaborators
Layout table for investigator information
Study Director: Emerging Oncology Medical Science Director, MD AstraZeneca

Additional Information:
Layout table for additonal information
Responsible Party: AstraZeneca Identifier: NCT00372944     History of Changes
Other Study ID Numbers: D1532C00008
First Posted: September 7, 2006    Key Record Dates
Last Update Posted: August 13, 2014
Last Verified: August 2014
Keywords provided by AstraZeneca:
advanced pancreatic cancer
metastatic pancreatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs